Immunogenic adverse events to CFTR modulators – An international survey
Open Access
- 19 March 2025
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 521-525
Abstract
No abstract availableKeywords
Funding Information
- Berlin Institute of Health at Charite
- Charité – Universitätsmedizin Berlin
- European Cystic Fibrosis Society
- Chiesi Farmaceutici
- Medical Research Foundation (MR/X00094X/1)
- Medical Research Council (MR/X00094X/1)
This publication has 22 references indexed in Scilit:
- Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)Journal of Cystic Fibrosis, 2024
- Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosisJournal of Cystic Fibrosis, 2022
- A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatmentJournal of Cystic Fibrosis, 2022
- Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapiesRespiratory Medicine, 2022
- At‐home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rashPediatric Pulmonology, 2022
- Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftorJournal of Cystic Fibrosis, 2022
- CFTR modulator drug desensitization: Preserving the hope of long term improvementPediatric Pulmonology, 2021
- Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotypePediatric Pulmonology, 2021
- Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytesJournal of Allergy and Clinical Immunology, 2021
- Hypersensitivity to antibiotics in patients with cystic fibrosisJournal of Cystic Fibrosis, 2014